Search Within

Catherine H Van Poznak

  1. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (7)
Groups
  1. Breast Medicine Service (18)
  2. Department of Medicine (18)
  3. Population Sciences Research Program (18)
  4. Solid Tumor Oncology Division (18)
  5. Survivorship Research (18)
  6. Biostatistics Service (15)

More Groups

People
  1. Clifford Hudis (18)
  2. Katherine Panageas (15)
  3. Larry Norton (14)
  4. Andrew Seidman (12)
  5. Gabriella D'Andrea-Carlino (10)
  6. Monica Fornier (10)

More People

Years
  1. 2007 (1)
  2. 2006 (6)
  3. 2005 (5)
  4. 2003 (3)
  5. 2002 (2)
  6. 2000 (1)
Publications
  1. Breast Cancer Research and Treatment (7)
  2. Journal of the American Geriatrics Society (3)
  3. Journal of Clinical Oncology (2)
  4. Bone (1)
  5. Cancer Investigation (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. Springer (7)
  2. Wiley Blackwell (4)
  3. American Association for Cancer Research (2)
  4. American Society of Clinical Oncology (2)
  5. BMJ Publishing Group Ltd. (1)
  6. Elsevier Science, Inc. (1)

More Publishers

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer
    Journal Article

    Modi, S.; DiGiovanna, M. P.; Lu, Z.; Moskowitz, C.; Panageas, K. S.; Van Poznak, C.; Hudis, C. A.; Norton, L.; Tan, L.; Stern, D. F.; more...
    Cancer Investigation (2005)

    Fulltext@MSK | Save
  • Phosphorylated/activated HER2 (P-HER2) as a marker of clinical resistance to single agent taxane chemotherapy for meta-static breast cancer (MBC)
    Meeting Abstract

    Modi, S.; DiGiovanna, M. P.; Lu, Z.; Moskowitz, C.; Panageas, K. S.; Van Poznak, C.; Hudis, C. A.; Norton, L.; Tan, L.; Stern, D. F.; more...
    Proceedings of the American Association for Cancer Research Annual Meeting (2003)

    Fulltext@MSK | Save
  • Osteoprotegerin expression correlates with ER/PR status in human breast tumors
    Meeting Abstract

    Van Poznak, C. H.; Cross, S. S.; Hudis, C.; Panageas, K. S.; Coleman, R. E.; Holen, I.
    Journal of Bone and Mineral Research (2003)

    Fulltext@MSK | Save
  • Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) are expressed in human breast tumors
    Meeting Abstract

    Van Poznak, C. H.; Cross, S. S.; Hudis, C.; Norton, L.; Panageas, K. S.; Coleman, R. E.; Holen, I.
    Breast Cancer Research and Treatment (2003)

    Fulltext@MSK | Save
  • Serum creatinine (Cr) values in patients with metastatic breast cancer (MBC) treated with pamidronate (PAM) administered as an intravenous 1 hour infusion (1 h)
    Meeting Abstract

    Van Poznak, C.; Ben-Porat, L.; Panageas, K.; Leone, D.; Seidman, A.; Hudis, C.
    Bone (2002)

    Fulltext@MSK | Save
  • Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer
    Journal Article

    Van Poznak, C.; Tan, L.; Panageas, K. S.; Arroyo, C. D.; Hudis, C.; Norton, L.; Seidman, A. D.
    Journal of Clinical Oncology (2002)

    Fulltext@MSK | Save
  • Clinical-pathologic assessment of the clinical sensitivity to single agent taxane (T) therapy for metastatic breast cancer (MBC)
    Meeting Abstract

    Van Poznak, C.; Tan, L.; Panageas, K.; Arroyo, C.; Hudis, C.; Norton, L.; Seidman, A. D.
    Breast Cancer Research and Treatment (2000)

    Fulltext@MSK | Save